Skip to main content

and
  1. No Access

    Article

    Summary of the proceedings of the United States and Japan Head and Neck Cancer Clinical Trials Summit, 19–20 September 1997, Kyoto, Japan

    Hidehiro Matsuura, David E. Schuller in Journal of Cancer Research and Clinical On… (1999)

  2. No Access

    Article

    Bone and soft tissue sarcomas: Summary of the Third United States/Japan Clinical Trials Summit (Seattle, Washington)

    Atsumasa Uchida, Masanori Fukushima in Journal of Cancer Research and Clinical On… (1997)

  3. No Access

    Article

    Summary of the Proceedings of the United States-Japan Lung Cancer Clinical Trials Summit

    Robert B. Livingston, Ryosuke Tsuchiva in Journal of Cancer Research and Clinical On… (1997)

  4. No Access

    Article

    Gastric and Esophageal Cancers: Perspectives from a U.S.-Japan Meeting

    Mace L. Rothenberg, Masanori Fukushima in Journal of Cancer Research and Clinical On… (1994)

  5. No Access

    Article

    Summary of a joint meeting between the Southwest Oncology Group and the Japanese Clinical Trials Consortium

    Mace L. Rothenberg, Charles A. Coltman Jr. in Journal of Cancer Research and Clinical On… (1993)

  6. No Access

    Article

    Phase II evaluation of bisantrene in refractory multiple myeloma

    Brian G. M. Durie, John Crowley, Charles A. Coltman Jr. in Investigational New Drugs (1991)

  7. No Access

    Article

    Phase II trial of intravenous melphalan for metastatic colorectal carcinoma

    Based on the high response rates seen among patients with colon cancer receiving high dose Melphalan with autologous marrow infusion, the Southwest Oncology Group conducted a Phase II trial of the compound at ...

    William A. Knight III, Phyllis Goodman, Sarah A. Taylor in Investigational New Drugs (1990)

  8. No Access

    Article

    Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease

    The Southwest Oncology Group has evaluated methyl-GAG on a weekly schedule among patients with lymphoma and Hodgkin's disease. Among 56 fully and partially evaluable patients responses were seen in 3 of 10 pat...

    William A. T. Knight III, Carol Fabian, John J. Costanzi in Investigational New Drugs (1983)

  9. No Access

    Article

    Mitoxantrone hydrochloride (NSC-310739) in lymphoma

    The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule. While the resu...

    Charles A. Coltman Jr., Terri M. McDaniel in Investigational New Drugs (1983)

  10. No Access

    Chapter

    Tumor Cloning Assay: Application and Potential Usefulness in Lung Cancer Management

    The use of the clonogenic or stem-cell assay in clinical practice has demonstrated exponential growth over the past five years. An attempt will be made to outline the development of this system, including both...

    S. Kent Callahan, Charles A. Coltman Jr. in Biology and Management of Lung Cancer (1983)

  11. No Access

    Article

    Activity of human leukocyte interferon in a human tumor cloning system

    Clinical trials using interferon to treat human malignancies are currently hampered by limited supplies of the compound. We have utilized a human tumor cloning system as an assay for the antitumor effects of h...

    Daniel D. Von Hoff, Jordan Gutterman, Barry Portnoy in Cancer Chemotherapy and Pharmacology (1982)

  12. No Access

    Chapter

    Treatment related leukemia

    The literature is replete with reports of the putative relationship of aggressive treatment of malignant, and even benign, disease and the development of acute myelogenous leukemia. Do these reports reflect an...

    Charles A. Coltman Jr. in Adult Leukemias 1 (1982)

  13. No Access

    Article

    Activity of 9–10 anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride (CL216,942) in a human tumor cloning system

    We have utilized a recently developed human tumor cloning system to screen for antitumor effects in vitro of a new anthracene derivative, CL216,942. The object was to determine whether the system is useful for...

    Daniel D. Von Hoff, Charles A. Coltman Jr in Cancer Chemotherapy and Pharmacology (1981)